Sequester, Shutdown Hurt FDA Recruitment, Morale – Hamburg
This article was originally published in The Rose Sheet
Executive Summary
The FDA commissioner tells a House subcommittee that a job candidate questioned whether the “uncertainty” of government work was worth leaving academia, reflecting sentiment that challenges the agency’s efforts to fill senior leadership positions.
You may also be interested in...
FDA Shutdown Lands Hard On CFSAN-Regulated Industries
The federal shutdown interrupts FDA’s increasing enforcement against firms marketing violative supplement products in addition to slowing drug application evaluations and facility inspections. FDA would retain 8,180 staff members, about 55% of its total, mostly because they could be “paid from carryover funding.”
Generics Approvals Will Decline, US FDA Predicts, But Supplement Work May Grow
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
Opioid 'Data Warehouse' Is Part Of US FDA's New Controlled Substances Program
CDER-based program lead by Marta Sokolowska will also handle benzodiazepine and stimulants activities and consult on relevant application assessments.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: